1.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9813, H8K-MC-JZAC, NCT00363766
|
|
2.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10409, H8K-MC-JZAF, NCT00383292
|
|
3.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10410, H8K-MC-JZAG, NCT00428610
|
|
4.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10408, H8K-MC-JZAD, H8K-MC-JZAD(a), NCT00490451
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12265, H8K-MC-JZAL, NCT00992225
|
|
6.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12266, H8K-MC-JZAJ, NCT00718159
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11158, H8K-MC-JZAE, NCT01215916
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10407, H8K-MC-JZAI, NCT01258348
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12267, H8K-MC-JZAK, NCT01284335
|